



**Aptamer Group and BizCom announce collaboration for Optimer services in Japan**

- *BizCom Japan Inc. and Aptamer Group Ltd have agreed a distribution and marketing agreement for services and products of Optimer discovery and development -*

York, UK and Tokyo, Japan (XX, 2021) - [Aptamer Group](#), Ltd. the developer of Optimer® binders to enable innovation in the life science industry, and [BizCom Japan](#), Inc. a Japan-based trading and consultancy company, today announce that they have entered into a distribution and marketing agreement.

This agreement gives BizCom non-exclusive rights to market and sell Optimer discovery and development services in Japan.

The Optimer platform consists of three integrated discovery processes that together increase the potential target range of Optimer binders. These nucleic acid-based affinity ligands offer faster discovery, increased batch consistency and increased stability, to remove the need for freezers and longer shelf life than protein-based alternatives, to deliver a range of advantages to scientists.

BizCom Japan, Inc. will use its extensive experience and sales and marketing expertise in Japan's life sciences space to market Aptamer Group's services in the region.

**Dr Arron Tolley, CEO of Aptamer Group said:** "We are delighted that we have established this clear route to market for Optimer discovery services in Japan, one of the largest pharma and medtech markets, with BizCom Japan. This is an important market for Aptamer Group and BizCom Japan are an excellent partner and are associated with well-known, established suppliers. They have an excellent reputation for customer support and a wide network throughout Japan."

**Dr Hiroyasu Nakatani, Executive Managing Director of BizCom Japan said:** "We are pleased to distribute custom Optimer services into the Japanese market. Optimers are unique affinity ligands showing specific binding activity, stability and offering novel solutions to researchers that cannot be achieved with alternative ligands, such as antibodies. To offer increased support to the life science market, we are delighted to bring this new technology to scientists in Japan."

- Ends-

**Enquiries:**

**Aptamer Group**

Jane McLeod (Content Marketing Manager) +44 (0)1904 567 790

[jane.mcleod@aptamergroup.com](mailto:jane.mcleod@aptamergroup.com)

**Alto Marketing (Scientific PR)**

David Robinson +44(0)1489 557672

[davidr@alto-marketing.com](mailto:davidr@alto-marketing.com)

**Consilium Strategic Communications (Corporate PR)**

Matthew Neal / Suki Virji / Lucy Featherstone +44(0)20 3709 5700

[aptamergroup@consilium-comms.com](mailto:aptamergroup@consilium-comms.com)

**Editor's notes**

**About Aptamer Group**

[Aptamer Group](#) develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions, that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are nucleic acid affinity ligands that can function as an antibody alternative. Despite many well-recognised problems with antibodies, the global antibody market is currently worth over \$145Bn. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists. Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.

**About BizCom Japan**

BizCom Japan, Inc. is a trading and consulting company based in Tokyo, Japan. From its foundation in 1996, it has been collaborating with various innovative companies in biotechnology, pharmaceutical, diagnostic, cosmetic and medical device industries. In addition to providing research reagents, services and equipment to the life science research market, BizCom Japan actively intermediates in- and out-licensing of various cutting-edge technologies for its collaborators. Through strategic alliances with its collaborators, the Company aims to extend its reach around the world. More information is available at [www.bizcomjapan.co.jp](http://www.bizcomjapan.co.jp)